Press Releases
Filter By Year
March
February
-
February 25, 2026
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy -
February 23, 2026
Gilead Sciences to Present at Upcoming Investor Conferences -
February 23, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel -
February 17, 2026
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options -
February 10, 2026
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend -
February 10, 2026
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results -
February 06, 2026
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
January
-
January 27, 2026
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 -
January 21, 2026
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Filter By Year